Singapore Translational Cancer Consortium (STCC) was established in 2020 as a nationally coordinated initiative and network to synergize cancer research and translational capabilities across Singapore. It aims to bring together Singapore’s best basic, clinical and translational talent in Singapore, and advance global research and translational competitiveness to the next level by establishing and implementing collaborative cancer research programs originating from the local cancer research community as well as partnerships from the industry.
The consortium will integrate our partners such as NCCS, NCIS, CSI and A*STAR, to create a one-stop concept to coordinate and provide the cancer community and industry with an enabling research and innovative environment.
STCC represents a major opportunity for Singapore to be recognized as a global leader for selected Asian cancers in terms of research & translational capabilities, through building peaks of excellence and thought-leadership, and demonstrating healthcare and economic value creation through its synergistic platforms and programs. STCC focuses on research that demonstrate potential for high-impact value-based applications in health & healthcare, specifically in cancer prevention, screening, treatment and patient care in Singapore.
STCC is now in Phase 1 implementation, focusing on the operationalization of the four joint platforms.